About Us
David Bowman, Ph.D.
Bruno Villoutreix, Ph.D.
Katya Tsaioun, Ph.D.
Chief Executive Officer
David has over 30 years of experience with privately funded, angel/venture backed and publically traded companies in the US and Europe.
He specializes in SaaS and biotech companies. He founded four companies in the US and his experience in the software industry includes the roles of CEO, CTO, COO, Chief Software Arc
Chief Executive Officer
David has over 30 years of experience with privately funded, angel/venture backed and publically traded companies in the US and Europe.
He specializes in SaaS and biotech companies. He founded four companies in the US and his experience in the software industry includes the roles of CEO, CTO, COO, Chief Software Architect, He has worked with many Global 1000, major consulting firms and industry analysts. He has designed and built more than 40 software products during his career including products sold to Microsoft and other companies for over 400M USD. He was founder, interim CEO and CTO of Virtual Strategy, Inc., a company that specialized in cloud based, high performance big data analytics solutions using a proprietary data warehouse technology.
David was Chief Architect at Fidelity Investments Systems Company (4.5 trillion USD in assets) and created a secure highly scalable fault tolerant solution used to trade a substantial percentage of the US stock market.
At Gerber Scientific he designed CAD/CAM software. This software was used by most major manufacturing companies in the world. These companies include GE, Boeing, Ford, Saab, Daimler, and many others. The software also used to design the space shuttle, aircraft such as the Boeing 767, jet fighter aircraft, automobiles, etc.
He was Chief Architect and Director of Advanced Technology at Wang Laboratories and pioneered imaging, linguistic, AI and neural network technology. He build an information system for the US Department of Labor that serves over 200M persons in 29 states. PhD in Bioinformatics (Molecular Dynamics and HPC
Katya Tsaioun, Ph.D.
Bruno Villoutreix, Ph.D.
Katya Tsaioun, Ph.D.
Board Director
20+ years experience in academia and Boston area biotech industry; successful entrepreneur (founded Apredica, an ADME-Tox CRO in 2006, exit to Cyprotex, PLC (now Evotec)); expertise in ADME-Tox and mechanistic strategies for hit-to-lead, lead optimization and de-risking drug-discovery programs.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
Chief Innovation Officer
25+ years international experience at the interface between molecular medicine (cancer, complement system, blood coagulation), structural bioinformatics and chemoinformatics both in the private and academic sectors in USA, Finland, Sweden, Bulgaria, France. Research director at INSERM U1141, Hospital Robert Debré,
Chief Innovation Officer
25+ years international experience at the interface between molecular medicine (cancer, complement system, blood coagulation), structural bioinformatics and chemoinformatics both in the private and academic sectors in USA, Finland, Sweden, Bulgaria, France. Research director at INSERM U1141, Hospital Robert Debré, Paris, France. Biomolecular modeling, drug design, ADME-Tox prediction.
Mario DiPaola, Ph.D.
Usamah Kayyali, Ph.D.
Bruno Villoutreix, Ph.D.
Principal Investigator
Dr. Mario DiPaola is an experienced executive with a 25-year record in the biotechnology and pharmaceutical industries. He is the founder or co-founder of a number of companies, including Blue Stream Labs Inc., Oncovolution LLC, Therabene LLC and Higher-Order Technologies LLC. He is also the author of several patents and 50+ publications.
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Advisor
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts Universities, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide
Advisor
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts Universities, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide as a potential drug. He currently serves as Scientific Advisor for Akttyva.
Mark Tepper, Ph.D.
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Board Chairman
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has
Board Chairman
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded multiple companies based on novel technologies in the area of RNA interference, structure-based drug design, small molecule and protein therapeutics, biosensors, microfluidics and biomaterials. He has taken 2 of his companies public (RXii & CRBP) and sold one in a trade sale to KNSA.